Intellia Therapeutics' Rare Genetic Disorder Therapy Meets Main Goal in ...

Intellia Drug Hits Goal in Milestone for Gene Editing Technology

Intellia Therapeutics Inc. said its gene-editing treatment for a rare swelling disorder met its goal in a late-stage trial, paving the way for the potential first approval of a new, simpler way of modifying DNA.

Intellia is seeking FDA approval for what could be the first in vivo CRISPR gene editing therapy

The company's treatment for hereditary angioedema reduced attacks by 87% vs. placebo in a Phase 3 trial, clearing the way for a potential 2027 launch

Intellia files CRISPR drug after historic phase 3 readout

Intellia has reported the first-ever phase 3 results with an in vivo gene-editing therapy, CRISPR-based lonvo-z for hereditary angioedema.

Gene‑editing therapy cuts swelling attacks in late‑stage trial

Late-stage trial shows Intellia's one-time gene-editing therapy lonvoguran ziclumeran cut hereditary angioedema swelling attacks by 87% with a clean safety profile, supporting a potential 2027 U.S. launch

Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trial

Intellia Therapeutics said its Crispr-based treatment for hereditary angioedema met its goals in a Phase 3 trial, marking a milestone for gene editing.